サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536210

NTRK融合遺伝子陽性の進行固形がんの世界市場

NTRK Fusion Gene Positive Advanced Solid Tumors

出版日
ページ情報
英文 270 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
NTRK融合遺伝子陽性の進行固形がんの世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 270 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

NTRK融合遺伝子陽性の進行固形がんの世界市場は2030年までに5億2,770万米ドルに達する見込み

2023年に3億9,620万米ドルと推定されたNTRK融合遺伝子陽性の進行固形がんの世界市場は、2023年から2030年にかけてCAGR 4.2%で成長し、2030年には5億2,770万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである診断タイプは、CAGR 4.9％を記録し、分析期間終了までに3億80万米ドルに達すると予測されます。治療薬タイプの成長率は、分析期間中CAGR 3.3％と推定されます。

米国市場は1億790万米ドルと推定、中国はCAGR 7.9％で成長すると予測

米国のNTRK融合遺伝子陽性の進行固形がん市場は、2023年に1億790万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億1,360万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは7.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と3.2%と予測されています。欧州では、ドイツがCAGR 2.3%で成長すると予測されています。

世界のNTRK融合遺伝子陽性の進行固形がん市場- 主要動向と促進要因のまとめ

NTRK融合遺伝子陽性の進行固形がんは、神経栄養性チロシン受容体キナーゼ（NTRK）遺伝子が他の遺伝子と融合し、発がん性融合タンパク質の発現につながる特定の遺伝子異常によって定義されるがんのカテゴリーを表します。このような融合はまれであるが、肺がん、甲状腺がん、肉腫など様々なタイプの腫瘍で発生します。一般にNTRK遺伝子融合が存在すると、細胞分裂と生存を促進するTRKシグナル伝達が持続的に活性化されるため、腫瘍の成長と進行の可能性が高いことを示します。これらの融合遺伝子の同定は、TRK融合タンパク質の活性を特異的に阻害できる標的療法の使用の指針となるため、極めて重要です。高精度の遺伝子検査と分子診断学の出現により、NTRK融合遺伝子陽性の腫瘍患者をより正確に同定できるようになり、患者の転帰を大幅に改善するオーダーメイドの治療アプローチが容易になりました。

NTRK融合遺伝子陽性腫瘍に対する標的治療の開発は、プレシジョン・オンコロジーにおける重要なマイルストーンとなりました。ラロトレクチニブやエントレクチニブなどのTRK阻害剤として知られる薬剤は、腫瘍の起源や組織型に関係なく、NTRK遺伝子融合腫瘍の治療に高い有効性を示しています。これらの治療薬は、TRK融合タンパク質のキナーゼ活性を特異的に阻害することにより作用し、腫瘍の成長を止め、腫瘍サイズを縮小させることができました。larotrectinibとentrectinibの両剤は、NTRK遺伝子融合が確認された固形がんの治療薬としてFDAの承認を得ており、部位診断的がん治療へのシフトを示しています。この進展は、がん治療における遺伝子プロファイリングの重要性が高まっていることを浮き彫りにしており、体内の部位ではなく腫瘍の遺伝的特徴に基づいて、より個別化された効果的な治療計画を可能にします。現在進行中の臨床試験では、これらのTRK阻害剤および新しいTRK阻害剤の可能性が探求され続けており、がん領域における標的治療の理解と応用が拡大しています。

NTRK融合遺伝子陽性の進行固形がんを標的とした治療市場の成長は、遺伝子スクリーニング技術の進歩、がん領域における個別化医療に対する意識の高まり、複数の腫瘍型におけるTRK阻害剤の幅広い有効性など、いくつかの要因によってもたらされています。強化された遺伝子検査機能により、NTRK阻害剤の恩恵を受けることができる患者をより正確に特定することができるため、治療結果や資源配分が最適化されます。さらに、ヘルスケア部門が精密医療を重視するようになったことで、標的療法の導入が促進され、腫瘍学の遺伝子研究に対する政策転換や資金増が後押ししています。がん治療がより個別化されるにつれ、消費者行動にも大きな変化が生じており、患者はより優れた有効性と副作用の軽減を約束するゲノム検査や個別化された治療計画をますます求めるようになっています。さらに、TRK阻害剤による臨床成績の成功が継続的な投資と研究に拍車をかけ、耐性メカニズムを克服したり、患者の耐性を改善したりする可能性のある次世代TRK阻害剤の開発につながっています。このような動向は、がん治療薬市場においてニッチでありながら極めて重要な分野であるTRK阻害剤の拡大を後押ししており、よりターゲットを絞った効果的ながん治療戦略への包括的な動きを反映しています。

調査対象企業の例（注目の86社）

  • Amoy Diagnostics Co., Ltd.
  • AnHeart Therapeutics
  • ARUP Laboratories
  • Bayer AG
  • CD Genomics
  • Chugai Pharmaceutical Co., Ltd.
  • Empire Genomics LLC
  • EntroGen, Inc.
  • F. Hoffmann-La Roche AG
  • GenPath
  • Illumina, Inc.
  • LGC Standards
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • Thermo Fisher Scientific, Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26651

Global NTRK Fusion Gene Positive Advanced Solid Tumors Market to Reach US$527.7 Million by 2030

The global market for NTRK Fusion Gene Positive Advanced Solid Tumors estimated at US$396.2 Million in the year 2023, is expected to reach US$527.7 Million by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Diagnostics Type, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$300.8 Million by the end of the analysis period. Growth in the Therapeutics Type segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$107.9 Million While China is Forecast to Grow at 7.9% CAGR

The NTRK Fusion Gene Positive Advanced Solid Tumors market in the U.S. is estimated at US$107.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$113.6 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global NTRK Fusion Gene Positive Advanced Solid Tumors Market - Key Trends and Drivers Summarized

NTRK fusion gene positive advanced solid tumors represent a category of cancer defined by specific genetic anomalies where neurotrophic tyrosine receptor kinase (NTRK) genes are fused with other genes, leading to the expression of oncogenic fusion proteins. These fusions are rare but occur across a variety of tumor types, including lung cancer, thyroid cancer, sarcoma, and others. The presence of NTRK gene fusions generally indicates a high likelihood of tumor growth and progression due to the continuous activation of TRK signaling, which promotes cell division and survival. Identification of these fusions is critical as it guides the use of targeted therapies that can specifically inhibit the activity of TRK fusion proteins. The advent of high-precision genetic testing and molecular diagnostics has enabled more accurate identification of patients with NTRK fusion-positive tumors, facilitating tailored treatment approaches that significantly improve patient outcomes.

The development of targeted therapies for NTRK fusion gene positive tumors has been a significant milestone in precision oncology. Drugs known as TRK inhibitors, such as larotrectinib and entrectinib, have shown high efficacy in treating tumors with NTRK gene fusions, regardless of the tumor’s origin or histology. These therapies work by specifically blocking the kinase activity of the TRK fusion proteins, thereby halting tumor growth and reducing tumor size. Both larotrectinib and entrectinib have received FDA approval for the treatment of any solid tumor with a confirmed NTRK gene fusion, marking a shift towards site-agnostic cancer treatment. This development highlights the growing importance of genetic profiling in cancer therapy, enabling more personalized, effective treatment plans based on the genetic characteristics of a tumor rather than its location in the body. Ongoing clinical trials continue to explore the potential of these and newer TRK inhibitors, expanding our understanding and application of targeted treatments in oncology.

The growth in the market for treatments targeting NTRK fusion gene positive advanced solid tumors is driven by several factors, including advancements in genetic screening technologies, increased awareness of personalized medicine in oncology, and the broad efficacy of TRK inhibitors across multiple tumor types. Enhanced genetic testing capabilities allow for more precise identification of patients who can benefit from NTRK inhibitors, thus optimizing treatment outcomes and resource allocation. Furthermore, the healthcare sector's growing emphasis on precision medicine has encouraged the adoption of targeted therapies, supported by policy shifts and increased funding for genetic research in oncology. As cancer treatments become more personalized, there is also a significant shift in consumer behavior, with patients increasingly seeking out genomic testing and personalized treatment plans that promise better efficacy and fewer side effects. Additionally, the successful clinical outcomes associated with TRK inhibitors have spurred ongoing investment and research, leading to the development of next-generation TRK inhibitors that may overcome resistance mechanisms or improve patient tolerance. These trends collectively drive the expansion of this niche yet crucial segment of the cancer therapeutics market, reflecting an overarching move towards more targeted, effective cancer care strategies.

Select Competitors (Total 86 Featured) -

  • Amoy Diagnostics Co., Ltd.
  • AnHeart Therapeutics
  • ARUP Laboratories
  • Bayer AG
  • CD Genomics
  • Chugai Pharmaceutical Co., Ltd.
  • Empire Genomics LLC
  • EntroGen, Inc.
  • F. Hoffmann-La Roche AG
  • GenPath
  • Illumina, Inc.
  • LGC Standards
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • Thermo Fisher Scientific, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • NTRK Fusion Gene Positive Advanced Solid Tumors - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of NTRK Fusion Gene Positive Tumors Throws the Spotlight On Targeted Therapies
    • Advances in Genetic Testing Drive Adoption of Personalized Cancer Treatments
    • Rising Global Cancer Incidence Strengthens the Business Case for NTRK-Targeted Therapies
    • Insurance Coverage and Reimbursement Policies for Genetic Testing Drive Market Acceptance
    • Regulatory Fast-Tracking of Promising Oncology Drugs Accelerates Time to Market
    • Integration of NTRK Testing in Routine Cancer Diagnostics Throws the Spotlight On Early Detection
    • Growing Demand for Non-Chemotherapy Cancer Treatments Generates Opportunities for NTRK Inhibitors
    • Emerging Data on Long-Term Efficacy and Safety of NTRK Inhibitors Sustain Market Confidence
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diagnostics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diagnostics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Diagnostics Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Therapeutics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Therapeutics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Therapeutics Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Cancer Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cancer Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • NTRK Fusion Gene Positive Advanced Solid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Diagnostics Type and Therapeutics Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by Type - Percentage Breakdown of Value Sales for Diagnostics Type and Therapeutics Type for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for NTRK Fusion Gene Positive Advanced Solid Tumors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer Centers End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION